FINWIRES · TerminalLIVE
FINWIRES

$IONS

6 stories mentioning IONS

Every FINWIRES story that references IONS, newest first.

Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing

Spencer R Berthelsen, Director, on June 01, 2026, sold 8,000 shares in Ionis Pharmaceuticals (IONS) for $605,360. Following the Form 4 filing with the SEC, Berthelsen has control over a total of 156,083 common shares of the company, with 156,013 shares held directly and 70 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000188/xslF345X05/edgardoc.xml

$IONS
Research

Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $92 from $86 based on our discounted cash flow analysis. We widen our 2026 loss per share forecast to -$2.62 from -$2.42 and our 2027 loss per share estimate to -$0.66 from -$0.35. IONS demonstrated significant positive momentum, reporting a very strong Q1 and significantly beating revenue and LPS estimates. Total Q1 revenue surged to $246M (+87% Y/Y) driven by robust operational execution and accelerating demand for Ionis' key commercial products. TRYNGOLZA (Olezarsen) sales rose by a record 350% Y/Y and DAWNZERA sales increased by 125% Q/Q in Q1. The upcoming launch of Olezarsen in severe hypertriglyceridemia (sHTG) indication targets a large addressable market of over 3 million patients and positions the treatment to be Ionis' first wholly-owned blockbuster medicine, in our view. We think the pipeline progress and successful operational execution position Ionis well for substantial near-term growth, reinforcing its evolution into a fully integrated commercial biotech company.

$IONS
Wire

Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating

Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $105.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $75.25, Change: $+0.42, Percent Change: +0.55%

$IONS
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS
Wire

Ionis Pharmaceuticals Reports Significant Results for Zilganersen in Alexander Disease Trial

Ionis Pharmaceuticals (IONS) said a study shows its zilganersen 50 mg demonstrated statistically significant results in patients aged five and older living with Alexander disease, a rare and often fatal neurodegenerative disorder.The pivotal study met its primary endpoint with the drug showing clinically meaningful stabilization of gait speed as assessed by the 10-meter walk test in patients, the company said Tuesday in a statement.New data from the Gross Motor Function Measure-88 showed that younger children aged two to four who received zilganersen improved more in gross motor function than those in the study's control group, the company said.Zilganersen demonstrated a favorable safety and tolerability profile, with most adverse events mild or moderate in severity, Ionis said.The drug is under priority review at the US Food and Drug Administration, which is expected to make an approval decision by Sept. 22, Ionis said.Price: $75.13, Change: $+0.25, Percent Change: +0.34%

$GE$IONS
Research

Canaccord Genuity Initiates Coverage on Ionis Pharmaceuticals With Buy Rating, $110 Price Target

Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $103.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$IONS